Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.83 -0.31 (-1.14%)
Streaming Delayed Price Updated: 2:27 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,049,016
Open 27.15
Bid (Size) 26.82 (3)
Ask (Size) 26.83 (3)
Prev. Close 27.14
Today's Range 26.73 - 27.22
52wk Range 25.92 - 44.47
Shares Outstanding 388,132,400
Dividend Yield 1.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga

Performance

YTD
-31.90%
-31.90%
1 Month
-11.36%
-11.36%
3 Month
-12.63%
-12.63%
6 Month
-25.22%
-25.22%
1 Year
-33.24%
-33.24%

More News

Read More
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Earnings Outlook For Royalty Pharma
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Royalty Pharma Reports Second Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
Via The Motley Fool
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Third Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.